Semaglutide vs. Tirzepatide: Which Is Right for You?
Both medications produce significant weight loss. But they work differently, have different efficacy profiles, and may suit different patients. Here's an evidence-based comparison from a board-certified obesity medicine physician.
Quick Comparison
Semaglutide
Brand names (not dispensed by Highland): Wegovy®, Ozempic®. Highland prescribes compounded semaglutide.
Semaglutide is a GLP-1 receptor agonist that mimics a naturally occurring hormone released after eating. It signals satiety to your brain, reduces appetite, and slows gastric emptying.
Tirzepatide
Brand names (not dispensed by Highland): Zepbound®, Mounjaro®. Highland prescribes compounded tirzepatide.
Tirzepatide acts at both GIP and GLP-1 receptors. Mechanism alone does not determine candidacy or predict an individual result.
Head-to-Head Comparison
How the medications differ in mechanism, administration, risks, monitoring, access, and patient-specific fit.
| Metric | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism of Action | GLP-1 receptor agonist | Dual GIP + GLP-1 agonist |
| Maximum Dose | 2.4mg weekly | 15mg weekly |
| Titration Period | 16-20 weeks to max dose | 20+ weeks to max dose |
| A1c Reduction (Diabetic Patients) | ~1.5% | ~2.0% |
| FDA Approval for Weight Loss | June 2021 (longer track record) | November 2023 |
| Clinical Data | STEP trials (more extensive) | SURMOUNT trials |
How We Use Clinical Evidence
Trials of FDA-approved products inform clinical discussion, but they do not establish the safety, effectiveness, quality, or expected outcomes of Highland's compounded formulation or predict an individual result.
Side Effects Comparison
Both medications have similar GI side effects, though rates differ slightly.
Common Side Effects (Both)
- Nausea (typically improves after 2-4 weeks)
- Diarrhea or constipation
- Decreased appetite (this is the goal)
- Mild stomach discomfort
- Fatigue during dose titration
- Injection site reactions (rare)
Key Differences
- Nausea rates: Similar between both (~15-25%), though some patients tolerate one better than the other
- GI side effects: Generally comparable; slow titration helps with both
- Tirzepatide advantage: Some studies suggest slightly better tolerability at equivalent efficacy
- Individual variation: Response and tolerability vary significantly between patients
Who Should Consider Each?
While both are excellent options, certain factors may favor one over the other.
Consider Semaglutide If:
- You want a medication with a longer track record
- You've responded well to GLP-1s in the past
- You prefer more extensive long-term safety data
- Cost/insurance favors semaglutide for you
- You need a lower starting dose (more titration options)
Consider Tirzepatide If:
- You want to compare the mechanisms, evidence, risks, and tradeoffs of available options
- You've plateaued on semaglutide
- You want to compare mechanisms, risks, access, and treatment tradeoffs
- You didn't tolerate semaglutide well
- You want the dual-mechanism approach
The Bottom Line
A head-to-head trial of FDA-approved products found a greater average reduction in body weight with tirzepatide, but that does not establish outcomes for Highland's compounded formulations. Individual response and tolerability vary.
The best choice depends on your health history, goals, insurance coverage, and how your body responds. That's why we don't just prescribe—we monitor, adjust, and optimize.
"Medication choice matters, but so do contraindications, tolerability, access, nutrition, resistance training, and follow-up. We may use DEXA to estimate changes in fat mass and lean mass and reassess the plan over time."
— Dr. Josh Lindsley, DO, DABOM
Frequently Asked Questions
A head-to-head trial of FDA-approved products found a greater average reduction in body weight with tirzepatide, but it did not evaluate Highland's compounded formulations and should not predict an individual result. Choice also depends on medical history, risks, tolerability, access, and goals.
A switch may be considered after clinician review. Timing and dosing depend on the current product, adverse effects, medical history, contraindications, and prescribed plan; patients should not switch or overlap medications on their own.
Coverage and retail pricing for FDA-approved products vary. Highland's compounded semaglutide and tirzepatide programs have separate pricing disclosed during the consultation; compounded drugs are not FDA-approved.
Both can lead to muscle loss if nutrition isn't optimized—up to 40% of weight lost can be lean mass. This is why we monitor body composition with DEXA scans and work with our registered dietitian to ensure adequate protein intake and preserve muscle mass.
The best medication depends on your health history, weight loss goals, insurance coverage, and individual response. During your consultation, we'll review your medical history, discuss your goals, and recommend the option most likely to work for you. We can also adjust course based on your response.
Ready to Start Your Weight Loss Journey?
Book a consultation to discuss which GLP-1 medication is right for you. We'll create a personalized protocol with body composition tracking and ongoing optimization.
Compounded medication disclaimer: Highland discusses FDA-approved options first and limits compounding to documented patient-specific needs. We do not dispense Wegovy®, Ozempic®, Zepbound®, or Mounjaro®. The clinical trial data discussed on this page comes from studies of brand-name products. Compounded medications are prepared by a state-licensed compounding pharmacy under physician supervision and are not FDA-approved.